journal article·1990-10

In Vivo Fate of End-Chain Radiolabelled Poly(β-malic acid), a Water-Soluble Biodegradable Drug Carrier

Philippe Fournie, Dominique Domurado, Philippe Guerin, Christian Braud, Michel Vert, Jean-Claude Madelmont

Publisher page

Abstract

In a first attempt to determine the fate of poly(β-malic acid) after intravenous injection in mice, polymer end-chain 14 C-radiolabelling was achieved using 14 C-triethylamine as the initiator for the ring-opening polymer ization of benzyl malolactonate. The corresponding poly(β-malic acid) sodium salt ( M w ∼ 30,000) exhibited an activity of 4.2 μCi :g -1 . Aliquots of a neutral isoosmotic solution of the latter were given intravenously to mice through a lateral tail vein. Radioactivity was counted in the liver, kidney, intestine, lung, brain, spleen, heart, muscle, urine and blood for various post-injection times up to 24 hours. Fast urinary excretion (70% after 1 hour and 90% after 6 hours) was observed. For all the sites investigated, radioactivity decreased exponen tially except in the liver and kidneys where a small peak was detected after 2 hours. Further investigations with poly(β-malic acid) radiolabelled in repeat ing units will be necessary to overcome the shortcomings of the end-chain radiolabelling method applied to degradable polymers.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Radiopharmaceutical Chemistry and Applications · Nanoparticle-Based Drug Delivery · Supramolecular Chemistry and Complexes

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Laboratoire de Technologie Enzymatique U.R.A. n° 523 du C.N.R.S. Université de Compiègne BP 649, 60206 Compiègne Cedex, France

U.R.A. n° 500 du C.N.R.S.-Université de Rouen Laboratorie des Substances Macromoléculaires INSA de Rouen BP 8, 76131 Mont Saint Aignan Cedex, France

U71 INSERM CHR de Clermont-Ferrand BP 184, 63005 Clermont-Ferrand Cedex, France

References (27)

Show source-provided references
1. 10.1126/science.353506910.1126/science.3535069 ↗
2. Moulder, J.W. · 1962
3. Mims, C.A. · 1976
4. 10.1146/annurev.mi.39.100185.00032110.1146/annurev.mi.39.100185.000321 ↗
5. 10.1093/clinids/4.1.10410.1093/clinids/4.1.104 ↗
6. Tulkens, P. 1985. "The Design of Antibiotics Capable of an Intracellular Action: Potentialities and Problems" in Drug Targeting. P. Busi and A. Gumma, eds. Elsevier Science Publishers, pp. 179-194.
7. 10.1016/0167-7799(89)90064-410.1016/0167-7799(89)90064-4 ↗
8. 10.1128/AAC.31.3.41010.1128/AAC.31.3.410 ↗
9. 10.1016/0006-2952(74)90174-910.1016/0006-2952(74)90174-9 ↗
10. Swenson, C.E. · Crit. Rev. Microbiol. · 1988 · 15 · S1
11. Brison, J. · 1987
12. 10.1177/08839115880030010710.1177/088391158800300107 ↗
13. 10.1016/0092-8674(80)90402-X10.1016/0092-8674(80)90402-X ↗
14. Demignot, S. · Drug Design Deliu · 1987 · 1 · 333
15. Vert, M. · Polym. Prep. · 1979 · 20 · 608
16. 10.1002/masy.1986006011310.1002/masy.19860060113 ↗
17. Vert, M. · CRC Crit. Rev. Ther. Drug Carrier Syst. · 1986 · 2 · 291
18. Braud, C.
19. Braud, C. and M. Vert. 1984. "Poly(β-malic acid) as a Source of Polyvalent Drug Carriers: Possible Effects of Hydrophobic Substituents in Aqueous Media," in Polymers as Biomaterials. New York: Plenum Publishing Co., pp. 1-15.10.1007/978-1-4613-2433-1_1 ↗
20. 10.1007/BF0026211110.1007/BF00262111 ↗
21. Ferruti, P. · CRC Crit. Rev. Ther. Drug Carrier Syst. · 1986 · 2 · 175
22. 10.1007/BF0070847910.1007/BF00708479 ↗
23. 10.1002/masy.1986006012910.1002/masy.19860060129 ↗
24. Guérin, P. · Polymer Comm · 1987 · 28 · 11
25. Madelmont, J.-C. · J. Labelled Comp
26. Amersham Corporation. 1983. "NCS® Solubilizer for Liquid Scintillation Counting;' 2636 South Clearbrook Drive, IL 60005 USA.
27. 10.1177/08839115860010010510.1177/088391158600100105 ↗